Tempest Therapeutics, Inc. (TPST) Tops Q2 EPS by 13c

Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($0.79), $0.13 better than the analyst estimate of ($0.92).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)